This paper outlines the current schizophrenia landscape, key unmet needs, and the advent of muscarinic therapies, as well as their impact on the treatment paradigm. It also explores the challenges and opportunities manufacturers face in discovering, developing, and delivering these innovative therapies in schizophrenia.
